ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Rapid and Differential Diagnosis of Sepsis Stages Using an Advanced 3D Plasmonic Bimetallic Alloy Nanoarchitecture-Based SERS Biosensor Combined with Machine Learning for Multiple Analyte Identification.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Gold- or Silver-Nanoparticle SERS Platforms for Plasma-Based Diagnostics and AI-Driven Analysis.Sensors (Basel, Switzerland) · 2026Review
- SERS Mixture Recognition from Pure-Substance Spectra via Component Evidence Learning and Two-Stage Inference.Molecules (Basel, Switzerland) · 2026Article
- Localized surface plasmon resonance-based point-of-care testing for pediatric sepsis.Frontiers in pediatrics · 2026Review
- Analysis and Optimization of Rotationally Symmetric Au-Ag Alloy Nanoparticles for Refractive Index Sensing Properties Using T-Matrix Method.Nanomaterials (Basel, Switzerland) · 2025Article
- Rapid and Differential Diagnosis of Sepsis Stages Using an Advanced 3D Plasmonic Bimetallic Alloy Nanoarchitecture-Based SERS Biosensor Combined with Machine Learning for Multiple Analyte Identification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Rapid and accurate differential diagnosis of infections, sepsis, and septic shock is essential for preventing unnecessary antibiotic overuse and improving the chance of patient survival. To address this, a 3D gold nanogranule decorated gold-silver alloy nanopillar (AuNG@Au-AgNP) based surface-enhanced Raman scattering (SERS) biosensor is developed, capable of quantitatively profiling immune-related soluble proteins (interleukin three receptor, alpha chain: CD123, programmed cell death ligand 1: PD-L1, human leukocyte antigen-DR isotype: HLA-DR, and chitotriosidase: ChiT) in serum samples. The 3D bimetallic nanoarchitecture, fabricated using anodized aluminum oxide (AAO), features a uniform structure with densely packed nanogaps on the heads of Au-Ag alloy nanopillars, enabling fast, simple, and replicable production. The proposed biosensor achieves accurate results even with low detection limits (4-6 fM) and high signal consistency (relative standard deviation (RSD) = 1.79%) within a one-step multi-analytes identification chip with a directly loadable chamber. To enhance the diagnostic performance, a support vector machine (SVM) based machine learning algorithm is utilized, achieving 95.0% accuracy and 95.8% precision in classifying healthy controls, infections with and without sepsis, and septic shock. This advanced 3D plasmonic bimetallic alloy nanoarchitecture-based SERS biosensor demonstrates clinical usefulness for sepsis diagnosis and severity assessment, providing timely and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.